Üyetürk, Ümmügül

Profile Picture
Name Variants
Uyeturk, U.
Uyeturk U
UYETURK Ummugul
Ü., Üyetürk
Üyetürk, Ü.
Uyetürk U.
Ummugul Uyeturk
Uyeturk, Ummugul
Üyeturk, Ümmügül
Üyetürk Ü.
Üyeturk, Ü.
Ummugul UYETURK
Ümmügül, Üyetürk
Ümmügül Üyetürk
U Uyeturk
Uyeturk U.
Üyeturk U.
Üyetürk Ümmügül
Üyetürk Ü
Uyeturk Ummugul
Üyetürk U.
Üyetürk, Ümmügül
Ümmügül ÜYETÜRK
ÜYETÜRK Ümmügül
Job Title
Prof. Dr.
Email Address
ummugul.uyeturk@okan.edu.tr
ORCID ID
0000-0002-6839-2632)
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

3

Articles

3

Citation Count

0

Supervised Theses

0

Filters

2023 - 20243
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Citation Count: 0
    Anaplastic thyroid carcinoma case series
    (2024) Küçüköztaş, Nadire; Duman, Tuba Taslamacıoğlu; Düzcü, Selma Erdoğan; Rahatlı, Samed; Üyetürk, Ümmügül; Medikal Onkoloji / Medical Oncology
    Aim: Among the endocrine malignancies, thyroid carcinoma (TC) is the most common. However, anaplastic TC accounts for 1-2% of these cancers. The aim of this study was to evaluate the demographic and pathologic features, treatments, and survival of patients with anaplastic TC. Methods: Anaplastic TC patients who applied to our medical oncology clinics between 01.01.2012 -01.12.2018 were retrospectively evaluated. Results: A total of 8 patients were included in the study. There were 4 female and 4 male patients with a median age of 68 (minimum 61-maximum 83) years. The initial complaint of all patients was a fast-growing swelling in the neck. Six patients had total thyroidectomy. Two patients had anaplastic TC with a differential TC. Six patients were at stage 4C. The most common site of metastasis was the lung (75%). Five patients had received a median of 3 (1-6) cycles of chemotherapy. Radiotherapy was applied to 7 patients. All patients except one died during the follow-up period. The median survival time of the patients was 3 (2-15) months. Conclusion: Anaplastic TC, an aggressive tumor with high metastasic potential, has no effective treatment at present. Effective treatments are needed for this rare and aggressive disease. Developments in the molecular field are promising for the treatment of ATC.
  • Thumbnail Image
    Article
    Citation Count: 0
    Protective Effects of N-Acetyl Cysteine on Undescended Testis after Orchiopexy: A Rat-model Study
    (Coll Physicians & Surgeons Pakistan, 2023) Kemahli, Eray; Uyeturk, Ugur; Cetinkaya, Ayhan; Erimsah, Sevilay; Uyeturk, Ummugul; Gucuk, Adnan; Medikal Onkoloji / Medical Oncology
    Objective: To assess the effectiveness of utilising N-acetyl cysteine (NAC) to treat tissue damage brought on by undescended testis (UT) in rats after orchiopexy.Study Design: Experimental study.Place and Duration of the Study: Bolu Abant Izzet Baysal University, Bolu, Turkey, from January 2018 to June 2020.Methodology: The UT model was created by administering flutamide to pregnant rats. Four groups of animals were created as the control group (offsprings of pregnant rats without flutamide), group II (UT), group III (UT + orchiopexy), and group IV (UT + orchiopexy + NAC); each containing eight animals.Results: Group IV had a higher level of glutathione peroxidase than groups III and II (p=0.001 and p=0.002, respectively). Malondialde-hyde was reduced in group IV compared with groups III and II (both p<0.001). There were differences in mean apoptotic cell counts (ACC) among the groups (p<0.001). ACC in group IV was lower than in group III (p<0.001). Sperm counts were higher in group IV than in groups III and II, and in group III they were higher than group II (p<0.001 all) and similar between groups IV and control group (p=0.102).Conclusion: Orchiopexy reduced UT-related testicular damage, additionally using NAC following orchiopexy may further reduce testic-ular damage through its antioxidant effects.
  • Thumbnail Image
    Article
    Citation Count: 0
    Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
    (Taylor & Francis Ltd, 2024) Dulgar, Ozgecan; Turker, Sema; Basaran, Gul; Araz, Murat; Sumbul, Ahmet Taner; Caglayan, Dilek; Gumus, Mahmut; Medikal Onkoloji / Medical Oncology
    We aimed to evaluate the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab plus trastuzumab and taxane. We reviewed the medical records of patients who were diagnosed with Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer and received pertuzumab and then TDM-1 between January 2014 and January 2021 from twenty- five cancer centers. The Kaplan- Meier method estimated progression-free survival (PFS) and overall survival (OS). Additionally, objective response rate (ORR), clinical benefit rate (CBR), and safety were evaluated. One hundred fifty-three patients were included,79.1% of the patients received TDM-1 in the second line, 90.8% had visceral metastasis, and 30.7% had central nervous system involvement. The PFS and OS of TDM-1 were evaluated according to the number of previous lines (on the 2nd line or more than two lines) metastatic sites (visceral and non-visceral) and the presence of central nervous metastasis. In TDM-1 therapy, PFS in second line therapy was ten months (95% CI: 7.7 - 12.2); this was statistically higher than later-line PFS, which was six months (95% CI: 3.3 to 8.6) (p = 0.004). The median OS time was 25 months (95% CI: 21.0 to 28.9) in patients treated with TDM-1 in the second line and 19 months (95% CI: 12.3 to 25.6) in patients who received later than the second line(p = 0.175). There were no significant differences in PFS time of patients with and without visceral and central nervous metastases. Our study showed that TDM-1 was also effective in patients using pertuzumab, contributes significantly to PFS when used in the second line compared to its use in the later line, and does not make any difference in OS.